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Available online 29 October 2016Introduction: There are several important interactions between antiepileptic drugs (AEDs) and hormonal contra-
ception that need to be carefully considered bywomenwith epilepsy (WWE) and their practitioners. Many AEDs
induce hepatic enzymes and decrease the efﬁcacy of hormonal contraception. In addition, estrogen-containing
hormonal contraception can increase the metabolism of lamotrigine, the most commonly prescribed AED in
women of childbearing age. The intrauterine device (IUD) is a highly effective form of reversible contraception
without AED drug interactions that is considered by many to be the contraceptive of choice for WWE. Women
with epilepsy not planning pregnancy require effective contraceptive counseling that should include discussion
of an IUD. There are no guidelines, however, on who should deliver these recommendations. The objective of this
studywas to explore the hypothesis that contraceptive counseling by a neurologist can inﬂuence the contraceptive
choices of WWE. In particular, we explored the relationship between contraceptive counseling in the epilepsy
clinic and the likelihood that patients would obtain an IUD.
Methods:We conducted a retrospective chart review of female patients age 18–45 seen at our institution for an
initial visit between 2010 and 2014 to ascertain the type of contraceptive counseling each patient received as
well as AED use and contraceptive methods. Patients who were pregnant or planning pregnancy at the ﬁrst visit
were excluded from further analyses as were patients with surgical sterilization. We also examined a subgroup
of 95 patients with at least 4 follow-up visits to evaluate the efﬁcacy of epileptologists' counseling. Speciﬁcally,
we looked at the likelihood a patient obtained an IUD based on the type of counseling she had received. Fisher
exact tests assessed associations between counseling type and whether patients had obtained an IUD.
Results: Three hundred and ninety-seven women met criteria for inclusion. Only 35% of female patients were
counseled about contraception at the ﬁrst visit. If women were not counseled at the ﬁrst visit, they were unlikely
to be counseled at subsequent visits; only 37% had ever received counseling by their fourth visit. Of the 95 patients
who completed 4 visits, 28.4% were counseled about an IUD as an optimal contraceptive choice, 38.9% were
generally counseled about contraceptive interactions, and 32.6% were not counseled about contraception.
Women with epilepsy who received IUD-speciﬁc counseling were signiﬁcantly more likely to switch to an IUD
(44.4%) compared with women who received no contraceptive counseling (6.5%; p = 0.0009). Women with
epilepsy who received IUD-speciﬁc counseling also tended to switch to an IUD more often than those women re-
ceiving general counseling about AEDs and contraceptive interactions (18.9%; p=0.027). Therewas no signiﬁcant
difference in the likelihood of acquiring an IUD between the general counseling and no counseling groups.
Conclusions: Contraceptive counseling by epileptologists and speciﬁc mention of an IUD is signiﬁcantly associated
with patient selection of an IUD as a contraceptive method. This suggests that neurologists can play an important
role in patients' contraceptive choices.
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rd).1. Introduction
1.1. Antiepileptic drugs and hormonal contraception
Epilepsy affects 0.5–1% of the population, and 33% of these individuals
are women of childbearing age [1]. It is critical that womenwith epilepsy
(WWE) plan their pregnancies in advance in order to minimize the tera-
togenic risk of antiepileptic drugs (AEDs) and optimize seizure control
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form of contraception is an important part of their health management
early in their care.
Obtaining appropriate contraception is complicated for WWE given
the bidirectional interactions between hormonal contraceptives and
themajority of AEDs. Enzyme-inducing AEDs (EI-AEDs) including carba-
mazepine, perampanel, phenobarbital, phenytoin, andprimidone arepo-
tent inducers of hepatic P450 microsomal enzymes. In addition, they
may increase sex hormone-binding globulin (SHBG) production. Both
mechanisms result in decreased bioactive sex hormone levels and re-
duce the effectiveness of hormonal contraception [2]. Clobazam,
eslicarbazepine, felbamate, lamotrigine, oxcarbazepine, and topiramate
induce P450 enzymes to a lesser degree but may also decrease sex ste-
roid concentrations and the efﬁcacy of hormonal contraception [2,3].
Estrogen-containing contraceptives such as the combined oral
contraceptive pills (COC), the vaginal ring, and patch enhance the
glucuronosyltransferase system resulting in increased metabolism
and lower serum concentrations of glucuronidated drugs including
lamotrigine and valproic acid [4–6].
1.2. Contraceptive recommendations for WWE
According to consensus statements from aWorld Health Organization
(WHO) working group and the Center for Disease Control (CDC),
combined oral contraceptive pills and progesterone only pills, as well
as contraceptive patches and vaginal rings are not recommended as
ﬁrst-line contraception in women taking EI-AEDs [2,7].
The statements mention that depot medroxyprogesterone and the
levonorgestrel implant can be considered in women taking EI-AEDs;
however, contraceptive failure has been reported when the levonorges-
trel implant was used in combination with EI-AEDs [2,7].
These statements from the WHO working group and the CDC as well
as other authors also recommend against combining lamotrigine and
estrogen-containing birth control methods (COCs, orthoevra patch, and
nuva ring) because of the risk of loss of seizure control [2,7]. While, in
practice, ﬂuctuations in lamotrigine levels can be avoided by an experi-
enced neurologist or epileptologist, it is preferable to avoid this variability.
An intrauterine device (IUD) is recommended as the contraceptive
of choice for WWE [3,8,9]. The IUD avoids all of the above drug–drug
interactions between contraception and AEDs. Additionally, the IUD is
an exceptionally effective form of contraception with a failure rate of
0.2–0.8% per year, which is superior to most hormonal contraceptive
methods and nonhormonal barrier methods such as male condoms
which with ‘typical use’ have a failure rate of 18% [10]. While it was
once thought that the IUD could only be used after childbirth, the IUD
is now recommended as a ﬁrst-line contraceptive choice for teenage
girls by the American Academy of Pediatrics [11]. The IUD does not
require consistent compliance as is needed with barrier methods or the
depot medroxyprogesterone injection. The copper IUD is approved for
10 years, and the 52-mg and 13.5-mg levonorgestrel IUDs are approved
for 5 and 3 years, respectively. Both the copper and levonorgestrel-
containing IUDs can be considered for WWE. The progestin, levonorges-
trel, in the levonorgestrel IUD, is thought to exert its effect locally and
not be subject to drug–drug interactions. In one study of 56 women
using the 52-mg levonorgestrel-containing and EI-AEDs, the failure rate
was 1.1% per year [12].
1.3. Contraceptive counseling
CounselingWWE about drug interactions and contraception is neces-
sary to prevent unintentional pregnancy and avoid breakthrough sei-
zures. However, there are no guidelines stating who is responsible for
relaying this critically important information to the patient. The aim of
the current study was to document the current contraceptive counseling
practices of epileptologists at our institution and to investigate whether
counseling by a neurologist was effective in inﬂuencing the contraceptivechoices of WWE. In particular, we chose to focus on the association be-
tween epileptologists' counseling and patient selection of an IUD, the
most efﬁcacious form of reversible birth control.
2. Methods
All study procedureswere approved by theNorthwestern University
Institutional Review Board. The study patients were women of child-
bearing age (18–45 years) seen as new patients in the Northwestern
University epilepsy clinic from 2010 to 2014. This cohort was selected
from all patients seen in our epilepsy clinic by Electronic Data Ware-
house (EDW) using the search terms “new patient”, “female”, “2010 to
2014”, and age “18 to 45”. Data were extracted by manual chart review
for each patient from the ﬁrst visit and up to 4 subsequent visits de-
pending on the number of follow-up appointments the patient
attended. The electronic medical record included a new patient intake
form with information regarding the patient's sexual and reproductive
history, plans for pregnancy, current medications, and birth control
which was used as an adjunct to the information documented in the
visit progress note. Patients were excluded based on information docu-
mented in the ﬁrst visit progress note or intake form. The exclusion
criteria included the following: surgical sterilization, current pregnancy,
or currently trying to become pregnant (Fig. 2.1.1).
For each visit, AED use and contraceptive methods as well as
counseling by the epileptologist were recorded as documented in the
patient's visit progress note. Counseling documentation was placed
into 1 of 3 groups: no counseling, general counseling, or IUD counseling.
“No counseling”— the physician did not document the occurrence of
counseling during the visit about interactions between AEDs and
contraceptives nor did the physician select “counseled about contra-
ceptive drug interactions” from the discussion dropdown menu in
the epilepsy template.
“General counseling” — physician documented discussion about con-
traception interactions in the visit note without speciﬁc mention of
an IUD, or “counseled about contraceptive drug interactions”was se-
lected from the discussion dropdownmenu in the epilepsy template.
“IUD counseling” — physician documented in the visit note that an
IUD was mentioned to the patient during contraceptive counseling.
A subgroup of female patients who had 4 visits at the epilepsy clinic
between 2010 and 2014 was used to investigate the effectiveness of the
current contraceptive counseling practices (Fig. 2.1.1). These women
were divided into 3 groups based on the type of counseling they received
at visit 1 or 2 as described above. Theoutcomes at visit 4weredocumented
as 1) changed to an IUD or 2) did not change to an IUD.Womenwho al-
ready had IUDs at the ﬁrst visit were excluded from this efﬁcacy cohort.
3. Statistical analysis
The presence or absence of counseling was documented for each
visit and is presented using descriptive statistics. Fisher exact tests
with 2x2 contingency tables were used to test the hypothesis that
counseling type (no counseling, general counseling, or IUD counseling)
was associatedwith patients' selection of an IUD for contraception. After
Bonferroni correction for multiple comparisons a p value of b0.0125
was used to determine statistical signiﬁcance.
4. Results
4.1. Patient population
Three hundred and ninety-seven new female patients seen in our
epilepsy clinic between 2010 and 2014 met criteria for inclusion in
Fig. 2.1.1. Sample size and reasons for exclusion at each visit. Efﬁcacy cohort included patients whohad completed four visits at the time of the study and did not have an IUD at the time of
ﬁrst visit.
Fig. 4.1.1.Antiepileptic drug (AED) use at each visit. The number of patients usingmultiple AEDs increaseswithmore visits with themajority of patients on polytherapy by the fourth visit.
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visit and numbers and reasons for exclusion. The patients ranged in age
from18 to 44with an average age of 28±7.3 years. The average time to
complete four visits was 14 ± 8.2 months with an average time be-
tween visits of 5.3 ± 4.8 months.
At the ﬁrst visit, AED monotherapy was the most common type of
treatment regimen (47%) followed by polytherapy (28%). Twenty-ﬁve
percent were not taking AEDs at the time of the ﬁrst visit. By the fourth
visit, themajority ofwomenwere receiving polytherapy (51%)with a sim-
ilar percentage onmonotherapy (48%). Only 3% of the patients completing
4 visitswere not prescribedAEDs (Fig. 4.1.1). At the fourth visit, themajor-
ity of patients (66%)were taking anAEDwith known interactionwithhor-
monal contraception: lamotrigine (45%), an EI-AEDother than lamotrigine
(20%), or both (11%). Six percentwere taking valproic acid. Further, 51% of
women changed their AED therapy at least once over the course of 4 visits.
4.2. Birth control use
At the ﬁrst visit, just over half of the women (53%) reported using
some form of contraception (Table 4.1.2). However, 16% of women re-
ported using no birth control, and data about birth control use and pref-
erencewere not available for 31.5% of thewomen as shown in Table 4.1.2
below. Of women taking AEDs at the ﬁrst visit, 14% reported using
condoms, 20% reported no current birth control method, and another
33% did not have contraceptive choice documented in the chart.
4.3. Contraceptive counseling
Of the 397womenwhomet criteria for the study, only 35% received
contraceptive counseling (either “general” or “IUD counseling”) at the
ﬁrst visit (Fig. 4.1.3). Further, women who were not counseled at the
ﬁrst visit were unlikely to be counseled at subsequent visits; only
26 counseling-naïve women received counseling at a follow-up visit
(Fig. 4.1.3).
4.4. Contraceptive counseling effectiveness
Womenwho attended 4 visits between 2010 and 2014were included
in the efﬁcacy cohort analysis to determine contraceptive counseling
effectiveness. Counseling group (IUD counseling, general counseling,
or no counseling) was determined by physician documentation as
previously described in the Methods section.
Patients who were speciﬁcally counseled about an IUDwere signiﬁ-
cantly more likely to change their contraceptivemethod to an IUD com-
pared with those who were never counseled (p = 0.0009) (Fig. 4.1.4).
Those who received IUD-speciﬁc counseling were also more likely to
get an IUD than those who received general counseling (p= 0.027), al-
though this did not reach strict statistical signiﬁcance. The comparison
between general and no counseling was not signiﬁcant (p = 0.167).
Analyses were repeated after excluding women who stated that theyTable 4.1.2
Birth control methods at ﬁrst visit (n = 397). Methods are listed from most to least
common with oral contraceptive pills being the most common documented method.
IUD = intrauterine device.
Birth control method Number of patients
(% of total, n = 397)
Not documented 125 (31.5%)
Oral contraceptive pillsa 106 (26.7%)
No birth control 66 (16.6%)
Condoms only 46 (11.6%)
IUD 31 (7.8%)
Etonogestrel/ethinyl estradiol vaginal ring 9 (2.3%)
Depot medroxyprogesterone 5 (1.3%)
Withdrawal and/or calendar method 8 (2.0%)
Etonogestrel implant 1 (0.3%)
a Three of 106 reported using oral contraceptive pills and condoms for birth control.were not sexually active (n = 14), and the effect of IUD counseling
remained signiﬁcant (p = 0.001) when compared with no counseling.
5. Discussion
Womenwith epilepsy, particularly those of childbearing age, require
contraceptive counseling as interactions between AED and birth control
may result in changes in seizure frequency or unplanned pregnancy.
Many women are unaware of these important drug–drug interactions
and their clinical implications [13]. However, there are no current
guidelines designating which providers are responsible for conveying
this important information.
In this study, WWE were variably counseled about interactions be-
tween AEDs and hormonal birth controlmethods at a single academic ep-
ilepsy center.Womenwhowere speciﬁcally counseled about an IUD as an
optimal form of birth control by their epileptologist were more likely to
obtain an IUD than those who were not counseled about contraception.
Those who were generally counseled about drug–drug interactions and
contraception by their epileptologist also tended to obtain IUDsmore fre-
quently than those who received no counseling at all. This suggests that
neurologistsmayplay an important role in patients' contraceptive choices.
It is easy to presume that patients may get appropriate counseling
from their gynecologist or other primary care providers, but this may
not be the case. The fact that only 6.5% of the women not receiving
counseling about an IUD in the epilepsy clinic elected to obtain an IUD
suggests that these patients are not learning about or are encouraged
to pursue this important option by other practitioners. Prior research
has suggested that many gynecologists are not knowledgeable about
the interactions between AEDs and hormonal contraception [14]. More-
over, these physicians may not be made aware when a patient changes
from a nonenzyme-inducing AED to an enzyme-inducing AED.
Another important ﬁnding of our study is that contraceptive
counseling is most likely to occur at the ﬁrst visit. Women were much
less likely to be counseled at subsequent visits, and 62% of women
who attended a fourth visit remained counseling-naïve. This is impor-
tant because, even if a woman is not on a drug with signiﬁcant contra-
ceptive interactions early in her treatment, her regimen is likely to
change. In our study, 51% of women changed their AED therapy at
least once over the course of four visits, and by the fourth visit, 66% of
women were taking an AED with known interaction with hormonal
contraception. Furthermore, 6% were taking valproic acid, which is asso-
ciated with signiﬁcant structural and cognitive teratogenesis. Many AED
changes occurred between visits without the opportunity for contracep-
tive counseling. Thus, contraceptive counseling should be accomplished
at least at the ﬁrst visit even if a patient is not sexually active or has
not yet been prescribed an AED thatmay interact with hormonal contra-
ception. Early counseling increases patients' awareness that AEDs
and contraceptive changes are relevant throughout the course of their
treatment during which several variables are likely to change.
This study focused on the recommendation of an IUD in order to
explore a direct association between one speciﬁc contraceptive recom-
mendation from a patient's neurologist and their contraceptive choice.
The IUD was selected because it is the most effective form of reversible
contraception [10], and experts agree that an IUD should be considered
the contraceptive of choice for the majority of women with epilepsy [3,8,
9]. An IUD is a good option for women who are not yet on a stable AED
regimen as it may avoid drug–drug interactions that arise with future
AED changes, which we found to be frequent in our cohort. However,
the IUD may not be the ideal contraceptive for every woman. There are
other forms of contraception, such as depot medroxyprogesterone, that
do not have signiﬁcant drug–drug interactions andmaybe better options
for some patients. We suspect that effective contraceptive counseling is
individualized andmay lead to different choices in certain patients. Nev-
ertheless, our study suggests that a discussion of speciﬁc contraceptive
options by an informed neurologist is likely associated with improved
contraceptive decision-making and more effective choices.
Fig. 4.1.3. Contraceptive counseling by visit. Bars indicate the number of patientswho attended each visit (total patients), number of patients at each visitwho had received counseling at a
prior visit (ever counseled), and number of patients counseled for the ﬁrst time at each visit (new counseling). Less than half of the patients were counseled at the ﬁrst visit, and very few
patients were counseled at subsequent visits.
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chart reviewmethodology. This study relies on accurate documentation
of birth control methods including documentation of an IUD. Certain
women may have been less likely to report on contraceptive use or be
counseled about contraception for reasons that could not be assessedFig. 4.1.4. Efﬁcacy of contraceptive counseling. Number of patients who switched to an IUD for b
Patients who received IUD-speciﬁc counseling were signiﬁcantly more likely to obtain an IUDretrospectively. It is also possible that those patients who were more
open or interested in discussing contraceptive practicesweremore like-
ly to change to an IUD. Additionally, because we wanted to make sure
that we allowed sufﬁcient time for patients to schedule appropriate
follow-up and institute a change in contraception, we limited this partirth control according to the type of counseling performed (none, general, or IUD-speciﬁc).
(*p = 0.002).
6 A.R. Espinera et al. / Epilepsy & Behavior 65 (2016) 1–6of the analysis to patients who had a total of 4 visits from 2010 to 2014.
This methodology may have selected for parents who were more likely
to follow recommendations as opposed to those patients who missed
follow-up appointments or had less regular visits. However, this should
have affected all counseling groups in a similar manner. Lastly, we
suspect that the epileptologist's role can be extrapolated to other
nonspecialty neurologists; however, because this study was conducted
at a single epilepsy specialty clinic, it is possible that it is not generaliz-
able for all neurology and epilepsy clinic settings.
Keeping these limitations in mind, this study suggests that contra-
ceptive counseling and documentation are not consistent and could be
improved. This is likely not limited to our center; in fact, the recently
published ﬁndings of The Epilepsy Birth Control Registry found that
only 25.4% of WWE consulted a neurologist about their contraceptive
choice [15]. An earlier survey of WWE found that only 55% of women
had discussed contraception with a healthcare provider and the discus-
sion was initiated by the healthcare provider only 27% of the time [16].
Over 36% of the women in this survey desired more information about
contraception and AEDs.
Our study demonstrates an association between the documentation
of contraceptive counseling and patient selection of an IUD, a highly
effective form of contraception without signiﬁcant drug–drug interac-
tions. This suggests that neurologists can play an important role in
contraceptive counseling for WWE and that these patients may not be
receiving this counseling from other sources. Accordingly, we propose
that contraceptive counseling for WWE should be performed by their
neurologist as well as their gynecologist and primary care providers
and each group of practitioners should apprise themselves of the infor-
mation needed to provide this important part of patient care. Formal
guidelines and education for neurologists on contraception for WWE
may help them provide this important counseling.Conﬂict of interest
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